The polycystic ovary syndrome (pcos) status and cardiovascular risk in young women

Central European Journal of Medicine

Volumn 6, Issue 1, 2011, Pages 64-75

  Ilie, Ioana R ^a   Pepene, Carmen E ^a   Marian, Ioan ^a   Mocan, Teodora ^a   Hazi, Georgeta ^a   Drăgotoiu, Gheorghe ^a   Ilie, Razvan ^a   Mocan, Lucian ^a   Duncea, Ileana ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Endothelin 1; Flow mediated vasodilation; High sensitive C reactive protein; Obesity; Polycystic ovary syndrome

Indexed keywords

C REACTIVE PROTEIN; ENDOTHELIN 1; TESTOSTERONE; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ARTERIAL WALL THICKNESS; ARTERY INTIMA PROLIFERATION; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HORMONAL REGULATION; HUMAN; METABOLIC REGULATION; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; TESTOSTERONE BLOOD LEVEL; VASODILATATION;

EID: 79251559391     PISSN: 18951058     EISSN: 16443640     Source Type: Journal    
DOI: 10.2478/s11536-010-0054-1     Document Type: Article

References (48)

1. Moran LJ, Pasquali R, Teede HJ, Hoeger KM, Norman RJ, Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society, Fertil. Steril., 2009, 92, 1966-1982
2. Glueck CJ, Morrison JA, Goldenberg N, Wang P, Coronary heart disease risk factors in adult premenopausal white women with polycystic ovary syndrome compared with a healthy female population, Metabolism 2009, 58, 714-721
3. Diamanti-Kandarakis E., Spina G., Kouli C., Migdalis I., Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy, J. Clin. Endocrinol. Metab., 2001, 86, 4666-4673
4. Orio F. Jr., Palomba S., Cascella T., De Simone B., Di Biase S., Russo T., Labella D., et al., Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 2004, 89,4588-4593
5. Orio F, Jr., Palomba S., Cascella T., De Simone B., Manguso F., Savastano S., et al., Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study, J. Clin. Endocrinol. Metab., 2005, 90, 6072-6076
6. Moran L.J., Hutchison S.K., Meyer C., Zoungas S., Teede HJ., A comprehensive assessment of endothelial function in overweight women with and without polycystic ovary syndrome, Clin. Sci. (Lond), 2009, 116,761-770
7. Kravariti M., Naka K.K., Kalantaridou S.N., Kazakos N., Katsouras C.S., Makrigiannakis A., et al., Predictors of endothelial dysfunction in young women with polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 2005, 90, 5088-5095
8. Arikan S., Akay H., Bahceci M., Tuzcu A., Gokalp D., The evaluation of endothelial function with flow-mediated dilatation and carotid intima media thickness in young nonobese polycystic ovary syndrome patients; existence of insulin resistance alone may not represent an adequate condition for deterioration of endothelial function, Fertil. Steril., 2009, 91,450-455
9. Diamanti-Kandarakis E., Alexandraki K., Protogerou A., Piperi C., Papamichael C, Aessopos A., et al., Metformin administration improves endothelial function in women with polycystic ovary syndrome, Eur. J. Endocrinol., 2005, 152,749-756
10. Diamanti-Kandarakis E., Alexandraki K., Piperi C., Protogerou A., Katsikis I., Paterakis T., et al., Inflammatory and endothelial markers in women with polycystic ovary syndrome, Eur. J. Clin. Invest., 2006, 36, 691-697
11. Tarkun I., Arslan B.C., Canturk Z., Turemen E., Sahin T., Duman C., Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation, J. Clin. Endocrinol. Metab., 2004, 89, 5592-5596
12. Brinkworth G.D., Noakes M., Moran L.J., Norman R., Clifton P.M., Flow-mediated dilatation in overweight and obese women with polycystic ovary syndrome, BJOG, 2006, 113, 1308-1314
13. Talbott E.O., Guzick D.S., Sutton-Tyrrell K., McHugh-Pemu K.P., Zborowski J.V., Remsberg K.E., Kuller L.H., Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women, Arterioscler. Thromb. Vasc. Biol., 2000, 20, 2414-2421
14. Vural B., Caliskan E., Turkoz E., Kilic T., Demirci A., Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome, Hum. Reprod., 2005, 20, 2409-2413
15. Costa L.O., dos Santos M.P., Oliveira M., Viana A., Low-grade chronic inflammation is not accompanied by structural arterial injury in polycystic ovary syndrome, Diabetes. Res. Clin. Pract., 2008, 81, 179-183
16. Carmina E., Orio F., Palomba S., Longo R.A., Cascella T., Colao A., et al., Endothelial dysfunction in PCOS: role of obesity and adipose hormones, Am. J. Med., 2006, 119, 356 e351-356
17. Diamanti-Kandarakis E., Paterakis T., Kandarakis H.A., Indices of low-grade inflammation in polycystic ovary syndrome, Ann. N. Y. Acad. Sci., 2006, 1092, 175-186
18. Gonzalez F., Rote N.S., Minium J., Kirwan J.P., Evidence of proatherogenic inflammation in polycystic ovary syndrome, Metabolism, 2009, 58, 954-962
19. Kaya C., Pabuccu R., Berker B., Satiroglu H., Plasma interleukin-18 levels are increased in the polycystic ovary syndrome: relationship of carotid intima-media wall thickness and cardiovascular risk factors, Fertil. Steril., 2009
20. Mohlig M., Spranger J., Osterhoff M., Ristow M., Pfeiffer A.F., Schill T., et al., The polycystic ovary syndrome per se is not associated with increased chronic inflammation, Eur. J. Endocrinol., 2004, 150, 525-532
21. Olszanecka-Glinianowicz M., Banas M., Zahorska- Markiewicz B., Janowska J., Kocelak P., Madej P., Klimek K., Is the polycystic ovary syndrome associated with chronic inflammation per se?, Eur. J. Obstet. Gynecol. Reprod. Biol., 2007, 133,197-202
22. Azziz R., Carmina E., Dewailly D., Diamanti- Kandarakis E., Escobar-Morreale H.F., Futterweit W., et al., Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline, J. Clin. Endocrinol. Metab., 2006, 91, 4237-4245
23. Rosei EA, Assessment of preclinical target organ damage in hypertension: carotid intima-media thickness and plaque, Blood. Press., 2003, 12, 185-186
24. Dagre A., Lekakis J., Mihas C., Protogerou A., Thalassinou L., Tryfonopoulos D., et al., Association of dehydroepiandrosterone-sulfate with endothelial function in young women with polycystic ovary syndrome, Eur. J. Endocrinol., 2006, 154, 883-890
25. Paradisi G., Steinberg H.O., Hempfling A., Cronin J., Hook G., Shepard M.K., Baron A.D., Polycystic ovary syndrome is associated with endothelial dysfunction, Circulation, 2001, 103, 1410-1415
26. Vryonidou A., Papatheodorou A., Tavridou A., Terzi T., Loi V., Vatalas I.A., et al., Association of hyperandrogenemic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 2005, 90, 2740-2746
27. Meyer C., McGrath B.P., Cameron J., Kotsopoulos D., Teede H.J., Vascular dysfunction and metabolic parameters in polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 2005, 90,4630-4635.
28. Higashiura K., Mathur R.S., Halushka P.V., Genderrelated differences in androgen regulation of thromboxane A2 receptors in rat aortic smoothmuscle cells, J. Cardiovasc. Pharmacol., 1997, 29, 311-315.
29. Chou T.M., Sudhir K., Hutchison S.J., Ko E., Amidon T.M., Collins P., et al., Testosterone induces dilation of canine coronary conductance and resistance arteries in vivo, Circulation, 1996, 94, 2614-2619.
30. Zitzmann M., Brune M., Kornmann B., Gromoll J., von Eckardstein S., von Eckardstein A., et al., The CAG repeat polymorphism in the AR gene affects high density lipoprotein cholesterol and arterial vasoreactivity, J. Clin. Endocrinol. Metab., 2001, 86, 4867-4873.
31. Rodriguez-Gonzalez G., Ramirez-Moreno R., Perez P., Bilbao C., Lopez-Rios L., Diaz-Chico J.C., The GGN and CAG repeat polymorphisms in the exon-1 of the androgen receptor gene are, respectively, associated with insulin resistance in men and with dyslipidemia in women, J. Steroid. Biochem. Mol. Biol., 2009, 113, 202-208.
32. Van Nieuwerburgh F., Stoop D., Cabri P., Dhont M., Deforce D., De Sutter P., Shorter CAG repeats in the androgen receptor gene may enhance hyperandrogenicity in polycystic ovary syndrome, Gynecol. Endocrinol., 2008, 24, 669-673.
33. Mather K.J., Verma S., Corenblum B., Anderson T.J., Normal endothelial function despite insulin resistance in healthy women with the polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 2000, 85, 1851-1856.
34. Meyer C., McGrath B.P., Teede H.J., Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease, J. Clin. Endocrinol. Metab., 2005, 90, 5711-5716.
35. Shroff R., Kerchner A., Maifeld M., Van Beek E.J., Jagasia D., Dokras A., Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis, J. Clin. Endocrinol. Metab., 2007, 92, 4609-4614.
36. Capoglu I. Erdem F., Uyanik A., Turhan H., Serum levels of resistin and hsCRP in women with PCOS, Cent. Eur. J. Med., 2009.
37. Talbott E.O., Zborowski J.V., Boudreaux M.Y., McHugh-Pemu K.P., Sutton-Tyrrell K., Guzick D.S., The relationship between C-reactive protein and carotid intima-media wall thickness in middle-aged women with polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 2004, 89, 6061-6067.
38. Orio F, Jr., Palomba S., Cascella T., Di Biase S., Manguso F., Tauchmanova L., et al., The increase of leukocytes as a new putative marker of low-grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 2005, 90, 2-5.
39. Diamanti-Kandarakis E., Paterakis T., Alexandraki K., Piperi C., Aessopos A., Katsikis I., et al.,Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin, Hum. Reprod., 2006, 21, 1426-1431.
40. Ilie I.R., Pepene C., Duncea I., Ilie R., Vascular abnormalities and low-grade chronic inflammation in women with polycystic ovary syndrome:Relationships with insulin resistance, obesity and hyperandrogenemia, Cent. Eur. J. Med., 2008, 3, 257-270.
41. Carmina E., Bucchieri S., Esposito A., Del Puente A, Mansueto P, Orio F, et al.,Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance, J. Clin. Endocrinol. Metab., 2007, 92, 2500-2505.
42. Puder J.J., Varga S., Kraenzlin M., De Geyter C., Keller U., Muller B., Central fat excess in polycystic ovary syndrome: relation to low-grade inflammation and insulin resistance, J. Clin. Endocrinol. Metab., 2005, 90, 6014-6021.
43. Cascella T., Palomba S., De Sio I., Manguso F., Giallauria F., De Simone B, et al.,Visceral fat is associated with cardiovascular risk in women with polycystic ovary syndrome, Hum. Reprod., 2008, 23, 153-159.
44. Tosi F. D.R., Castello R., Maffeis C., Spiazzi G., Zoppini G., Muggeo M., et al., Body fat and insulin resistance independently predict increased serum C-reactive protein in hyperandrogenic women with polycystic ovary syndrome, Eur. J. Endocrinol., 2009, 161, 737-745.
45. Kelly C.C., Lyall H., Petrie J.R., Gould G.W., Connell J.M., Sattar N., Low grade chronic inflammation in women with polycystic ovarian syndrome, J. Clin. Endocrinol. Metab., 2001, 86, 2453-2455.
46. McCrohon J.A., Jessup W., Handelsman D.J., Celermajer D.S., Androgen exposure increases human monocyte adhesion to vascular endothelium and endothelial cell expression of vascular cell adhesion molecule-1, Circulation, 1999, 99, 2317-2322.
47. Norata G.D., Tibolla G., Seccomandi P.M., Poletti A., Catapano A.L., Dihydrotestosterone decreases tumor necrosis factor-alpha and lipopolysaccharideinduced inflammatory response in human endothelial cells, J. Clin. Endocrinol. Metab., 2006, 91, 546-554.
48. Li S., Li X., Li Y., Regulation of atherosclerotic plaque growth and stability by testosterone and its receptor via influence of inflammatory reaction, Vascul. Pharmacol., 2008, 49,14-18.